These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38548226)

  • 1. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
    Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
    Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
    Brudno JN; Lam N; Vanasse D; Shen YW; Rose JJ; Rossi J; Xue A; Bot A; Scholler N; Mikkilineni L; Roschewski M; Dean R; Cachau R; Youkharibache P; Patel R; Hansen B; Stroncek DF; Rosenberg SA; Gress RE; Kochenderfer JN
    Nat Med; 2020 Feb; 26(2):270-280. PubMed ID: 31959992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.
    Wang W; He S; Zhang W; Zhang H; DeStefano VM; Wada M; Pinz K; Deener G; Shah D; Hagag N; Wang M; Hong M; Zeng R; Lan T; Ma Y; Li F; Liang Y; Guo Z; Zou C; Wang M; Ding L; Ma Y; Yuan Y
    Ann Rheum Dis; 2024 Sep; 83(10):1304-1314. PubMed ID: 38777376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
    Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
    Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.
    Kretschmann S; Völkl S; Reimann H; Krönke G; Schett G; Achenbach S; Lutzny-Geier G; Müller F; Mougiakakos D; Dingfelder J; Flamann C; Hanssens L; Gary R; Mackensen A; Aigner M
    Transplant Cell Ther; 2023 Jan; 29(1):27-33. PubMed ID: 36241147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.
    Amatya C; Weissler KA; Fellowes V; Lam N; Cutmore LC; Natrakul DA; Highfill SL; Kochenderfer JN
    Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101212. PubMed ID: 38455264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
    Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2021; 12():670088. PubMed ID: 34122428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
    Kambayana G; Surya Rini S
    Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
    Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
    J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
    Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
    [No Abstract]   [Full Text] [Related]  

  • 15. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.
    Abdalhadi HM; Chatham WW; Alduraibi FK
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.
    Fischbach F; Richter J; Pfeffer LK; Fehse B; Berger SC; Reinhardt S; Kuhle J; Badbaran A; Rathje K; Gagelmann N; Borie D; Seibel J; Ayuk F; Friese MA; Heesen C; Kröger N
    Med; 2024 Jun; 5(6):550-558.e2. PubMed ID: 38554710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
    Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.